// App-Quantinova.ai

557 : CA15-3/MUC1 in CCTG MA-32 (NCT01101438): A phase III RCT of the effect of metformin vs. placebo on invasive disease free and overall survival in early stage breast cancer (BC).

Researchers

Presenter

  • Ryan JO Dowling

Principal Investigators

  • Karen A. Gelmon

  • Lois E. Shepherd

  • Shakeel Virk

  • Marguerite Ennis

  • Fangya Mao

  • Jennifer A. Ligibel

  • Dawn L. Hershman

  • Priya Rastogi

  • Ingrid A. Mayer

  • Timothy J. Hobday

  • Julie Lemieux

  • Alastair Mark Thompson

  • Manuela Rabaglio-Poretti

  • Timothy Joseph Whelan

  • Vuk Stambolic

  • Bingshu E. Chen

  • Pamela Jean Goodwin

Medical Centers

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Canadian Cancer Trials Group, Kingston, ON, Canada

  • University of British Columbia and BC Cancer Agency, Vancouver, BC, Canada

  • Queen's University, Canadian Cancer Trials Group, Kingston, Ontario, CA, Kingston, ON, Canada

  • Applied Statistician, Markham, ON, Canada

  • Dana-Farber Cancer Institute, Boston, MA

  • Columbia University Medical Center, New York, NY

  • University of Pittsburgh Medical Center, Pittsburgh, PA

  • Vanderbilt-Ingram Cancer Center, Nashville, TN

  • Mayo Clinic, Rochester, MN

  • CHU de Quebec - Universite Laval, Quebec City, QC, Canada

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • IBCSG and University Hospital, Berne, Switzerland

  • Cancer Care Ontario, Hamilton, ON, Canada

  • University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada

Locations

  • United States

  • Canada

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Kerbs von Lungren 6 antigen

  • Cancer antigen 15-3

  • High sensitivity C-reactive protein

Drug/Treatment

  • Metformin Hydrochloride

  • CA15-3

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • NCT01101438

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved